News
News
Michelle JoinerNovember 6, 2025SeeTreat's ART.1 is now CE Marked under EU MDR - Bringing Adaptive Radiotherapy to Every ClinicÂ
SeeTreat announced today that its offline adaptive radiotherapy software, ART.1, has received CE Mark certification under the European Union Medical Device Regulation and is now available for clinical use across the European Union.
Read more
Prof. Jarad MartinOctober 19, 2025ART.1: Seamless, Safe, and Easy: A Radiation Oncologist's Perspective
Offline ART Remains the Go-To Approach As a radiation oncologist, I've seen the challenges of offline adaptive radiotherapy (ART) firsthand. Every department seems to have its own “secret sauce” for when to adapt a plan, and quite honestly, it all seems a little bit heuristic about what's being applied. That variability told me one thing: there's no universal standard, and that can make consistent, high-quality care difficult to achieve.
Read more
Adam ManoliJune 27, 2025What the Radiation Oncology Community is Saying About Adaptive Radiotherapy (ART): Insights from SeeTreat's LinkedIn Polls
Over the past few weeks, SeeTreat turned to LinkedIn to gather insights from the radiation oncology community on current practices and perspectives surrounding Adaptive Radiotherapy (ART). The results reveal both growing interest and the practical challenges of implementation.
Read more
Adam ManoliMay 21, 2025What's Holding Back Adaptive Radiation Therapy? A Look at the Tools Needed.
What's Holding Back Adaptive Radiation Therapy? A Look at the Tools Needed Adaptive radiation therapy (ART) holds immense potential to improve cancer care by reducing treatment-related toxicity and lowering recurrence rates. However, despite its clear clinical and economic benefits, adoption remains limited. In Australia, for example, only about 3% of patients currently receive adaptive radiotherapy, leaving 97% without access to this enhanced approach. A key reason is the significant number of technical tools, processes, and human resources required to deliver ART effectively.
Read more
Michelle JoinerApril 30, 2025SeeTreat to Launch ART.1 to Support Adaptive Radiotherapy at ESTRO 2025
SeeTreat will debut its first clinical product, ART.1, at Booth 820 during ESTRO 2025 in Vienna. ART.1 is a software as a medical device that delivers objective, evidence-based decision support for adaptive treatment re-planning in patients undergoing radiotherapy. ART.1 automatically calculates delivered dose and propagates daily contours based on each patient's volumetric imaging, while displaying and reporting key clinical metrics. Running silently in the background, ART.1 prioritizes only the patient cases needing attention—allowing clinical teams to focus their time where it matters most. The software adds efficient, adaptive-quality treatment capabilities on any standard linear accelerator—without hardware upgrades or workflow disruption.
Read more
Prof Paul KeallMarch 18, 2025Expanding Global Access to Offline Adaptive Radiotherapy
Prof. Keall discusses a game-changing approach to making offline adaptive evaluation more accessible to everyone. This is a unique opportunity to learn from a global leader in radiation oncology research and watch the live Q&A session following the presentation.
Read more